Neglected Tropical Diseases (NTDs)

Korea International Cooperation Agency (KOICA)

Antimicrobial resistance (AMR), Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Tuberculosis (TB), Uncategorized / By

The Korea International Cooperation Agency (KOICA) was established in April 1991 by the Korean Government as a governmental agency dedicated to providing grant aid programs. It operates both domestically and internationally as a development cooperation platform contributing to accomplish the Sustainable Development Goals (SDGS). Through its Global Disease Eradication Fund, KOICA partners with international non-governmental organisations and the private sector to prevent and eradicate infectious diseases in developing countries.

Initiative 5% (France)

Antimicrobial resistance (AMR), Euripo II programmes, Neglected Tropical Diseases (NTDs), Uncategorized / By

Initiative 5% is a facility implemented by the public agency Expertise France and complementing the Global Fund Initiative in building a more effective response to pandemics, with a focus on HIV/AIDS, malaria and tuberculosis, and strengthening the health impact of funded programmes for populations. Set up in 2011, it supports recipients in accessing Global Fund funding and improving the effectiveness of grants, mainly in French-speaking countries.

Global Health Innovative Technology Fund (GHIT Fund)

Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Tuberculosis (TB), Uncategorized / By

The Global Health Innovative Technology Fund (GHIT Fund) is an international public-private partnership between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome Trust, and United Nations Development Programme (UNDP). It facilitates global R&D partnerships for the discovery and development of new health technologies for the developing world and invests in these global R&D partnerships through a grant-making mechanism. Its portfolio covers drugs, vaccines, and diagnostics in infectious diseases, such as HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases.

United Kingdom Foreign, Commonwealth and Development Office (FCDO)

Antimicrobial resistance (AMR), Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Tuberculosis (TB), Uncategorized / By

The Foreign, Commonwealth and Development Office (FCDO) is the UK’s ministerial department responsible for foreign affairs and international development. A key FCDO priority is supporting research in infectious diseases, including developing new technologies and supporting health systems strengthening in low- and middle-income countries (LMICs). Among others, FCDO is working with the Bill & Melinda Gates Foundation (BMGF), CEPI, Wellcome Trust, the UK Department for Health and Social Care (DHSC), the Medical Research Council (MRC), and the WHO to drive forward the agenda on infectious disease preparedness.

Federal Ministry of Education and Research (BMBF)

Antimicrobial resistance (AMR), Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Tuberculosis (TB), Uncategorized / By

The Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) (BMBF) provides funding for research projects and institutions and has a department specifically devoted to Health Research. As part of the German Antibiotic Resistance Strategy, BMBF provides substantial support for research and development in antibiotic resistance through various funding opportunities. Key examples are the Global Antimicrobial Research and Development Hub (Global AMR R&D Hub), bringing together the European Commission, national governments, and international funding organisations, and InfectControl 2020, a research collaboration between research institutes and industrial companies.

Drugs for Neglected Diseases Initiative (DNDi)

Euripo II programmes, Neglected Tropical Diseases (NTDs), Uncategorized / By

The Drugs for Neglected Diseases Initiative (DNDi) is a not-for-profit research and development organisation founded by the World Health Organization (WHO) and five international research institutions. It is dedicated to the discovery, development, and delivery of affordable and patient-friendly treatments across the world, covering a range of historically neglected disease areas.

Australian Department of Foreign Affairs and Trade (DFAT)

Antimicrobial resistance (AMR), Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Tuberculosis (TB), Uncategorized / By

The Department of Foreign Affairs and Trade (DFAT)’s work in health supports international development cooperation on priority health issues. Within the Global Health division of DFAT, the Indo-Pacific Centre for Health Security invests in projects in the Pacific and Southeast Asia, including a focus on infection prevention and control and antimicrobial resistance (AMR). These project investments are complemented by targeted support for the work of key multilateral organisations in the region, including the World Health Organization (WHO).

United States Department of Defense (DOD)

Antimicrobial resistance (AMR), Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Uncategorized / By

The US Department of Defense (DOD) works with foreign nations to establish and develop international partnerships through joint medical training exercises and public health initiatives to support and strengthen the public health capabilities of partner nations, as well as to improve interoperability. The DOD also engages with non-government organisations, academia and private-sector organisations to enhance global health objectives.

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

Antimicrobial resistance (AMR), Euripo II programmes, Neglected Tropical Diseases (NTDs), Uncategorized / By

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global not-for-profit partnership led by Boston University and funded by a consortium of governments and foundations. It is dedicated to supporting early-stage antibacterial research and development of innovative therapeutics, preventatives and rapid diagnostics for drug-resistant bacteria. CARB-X focuses investment on projects that target priority pathogens, as identified by the World Health Organization (WHO) and the United States’ Centers for Disease Control and Prevention (CDC).

Clinton Health Access Initiative (CHAI)

Euripo II programmes, Malaria, Neglected Tropical Diseases (NTDs), Tuberculosis (TB), Uncategorized / By

The Clinton Health Access Initiative (CHAI) is a not-for-profit working closely with governments and the private sector to strengthen disease surveillance and data analysis, and support and scale up the delivery of preventive and therapeutic interventions, in low- and middle-income countries (LMICs). Originally focusing on HIV/AIDS, CHAI has expanded its focus to cover a host of infectious diseases, including malaria, tuberculosis, and neglected tropical diseases.

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide: https://ec.europa.eu/docsroom/documents/42921
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:
    Monitoring

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:
    Monitoring

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain